Cargando…
Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study
BACKGROUND: The Endocrine Society Clinical Practice Guidelines recommend the avoidance of medications that may cause weight gain (i.e., obesogenic medications) in individuals with overweight or obesity. Obesity disproportionately affects people with lower socioeconomic status (SES); however, it is u...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348594/ https://www.ncbi.nlm.nih.gov/pubmed/35928911 http://dx.doi.org/10.1016/j.lana.2022.100249 |
_version_ | 1784761948589522944 |
---|---|
author | Lyu, Beini Chang, Alex R. Inker, Lesley A. Selvin, Elizabeth Grams, Morgan E. Shin, Jung-Im |
author_facet | Lyu, Beini Chang, Alex R. Inker, Lesley A. Selvin, Elizabeth Grams, Morgan E. Shin, Jung-Im |
author_sort | Lyu, Beini |
collection | PubMed |
description | BACKGROUND: The Endocrine Society Clinical Practice Guidelines recommend the avoidance of medications that may cause weight gain (i.e., obesogenic medications) in individuals with overweight or obesity. Obesity disproportionately affects people with lower socioeconomic status (SES); however, it is unknown whether the use of obesogenic medications differs by SES. METHODS: We included adults with overweight or obesity and used prescription medications from 2009-2018 of the US National Health and Nutrition Examination Survey. We examined the associations between a composite measure of SES and use of obesogenic medications and anti-obesity medications. The composite SES included <high school education (1 point), household income below federal poverty level (1 point), no insurance (2 points), and public health insurance only (1 point). We defined 3 composite SES groups (0 [high], 1 [intermediate], and ≥2 points [low]). FINDINGS: Among 10,673 US adults with overweight or obesity, 20.0% had low SES. Use of obesogenic medications was common (37.7%). Low (vs. high) SES was associated with greater obesogenic medication use, independent of demographic characteristics, prescription medication burden, and comorbidities (OR 1.3 [1.2-1.5]). Among 12,133 eligible participants, utilization of anti-obesity medications was very low overall (0.5%) and within all SES groups (low 0.27%, intermediate 0.71, and high 0.65%). INTERPRETATION: Our findings highlight common and modifiable risk factors for obesity. Clinicians should screen patient medications for those that may cause weight gain and increase adoption of anti-obesity medications, especially among adults living in low SES. FUNDING: The National Institute of Diabetes and Digestive and Kidney Disease (R01DK115534, K24HL155861, and K01DK121825). |
format | Online Article Text |
id | pubmed-9348594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-93485942022-08-03 Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study Lyu, Beini Chang, Alex R. Inker, Lesley A. Selvin, Elizabeth Grams, Morgan E. Shin, Jung-Im Lancet Reg Health Am Articles BACKGROUND: The Endocrine Society Clinical Practice Guidelines recommend the avoidance of medications that may cause weight gain (i.e., obesogenic medications) in individuals with overweight or obesity. Obesity disproportionately affects people with lower socioeconomic status (SES); however, it is unknown whether the use of obesogenic medications differs by SES. METHODS: We included adults with overweight or obesity and used prescription medications from 2009-2018 of the US National Health and Nutrition Examination Survey. We examined the associations between a composite measure of SES and use of obesogenic medications and anti-obesity medications. The composite SES included <high school education (1 point), household income below federal poverty level (1 point), no insurance (2 points), and public health insurance only (1 point). We defined 3 composite SES groups (0 [high], 1 [intermediate], and ≥2 points [low]). FINDINGS: Among 10,673 US adults with overweight or obesity, 20.0% had low SES. Use of obesogenic medications was common (37.7%). Low (vs. high) SES was associated with greater obesogenic medication use, independent of demographic characteristics, prescription medication burden, and comorbidities (OR 1.3 [1.2-1.5]). Among 12,133 eligible participants, utilization of anti-obesity medications was very low overall (0.5%) and within all SES groups (low 0.27%, intermediate 0.71, and high 0.65%). INTERPRETATION: Our findings highlight common and modifiable risk factors for obesity. Clinicians should screen patient medications for those that may cause weight gain and increase adoption of anti-obesity medications, especially among adults living in low SES. FUNDING: The National Institute of Diabetes and Digestive and Kidney Disease (R01DK115534, K24HL155861, and K01DK121825). Elsevier 2022-04-02 /pmc/articles/PMC9348594/ /pubmed/35928911 http://dx.doi.org/10.1016/j.lana.2022.100249 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Articles Lyu, Beini Chang, Alex R. Inker, Lesley A. Selvin, Elizabeth Grams, Morgan E. Shin, Jung-Im Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study |
title | Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study |
title_full | Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study |
title_fullStr | Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study |
title_full_unstemmed | Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study |
title_short | Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study |
title_sort | socioeconomic status and use of obesogenic and anti-obesity medications in the united states: a population-based study |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348594/ https://www.ncbi.nlm.nih.gov/pubmed/35928911 http://dx.doi.org/10.1016/j.lana.2022.100249 |
work_keys_str_mv | AT lyubeini socioeconomicstatusanduseofobesogenicandantiobesitymedicationsintheunitedstatesapopulationbasedstudy AT changalexr socioeconomicstatusanduseofobesogenicandantiobesitymedicationsintheunitedstatesapopulationbasedstudy AT inkerlesleya socioeconomicstatusanduseofobesogenicandantiobesitymedicationsintheunitedstatesapopulationbasedstudy AT selvinelizabeth socioeconomicstatusanduseofobesogenicandantiobesitymedicationsintheunitedstatesapopulationbasedstudy AT gramsmorgane socioeconomicstatusanduseofobesogenicandantiobesitymedicationsintheunitedstatesapopulationbasedstudy AT shinjungim socioeconomicstatusanduseofobesogenicandantiobesitymedicationsintheunitedstatesapopulationbasedstudy |